Jade Biosciences (JBIO) Cash from Financing Activities (2021 - 2026)
Jade Biosciences posted quarterly Cash from Financing Activities of -$795000.0 for Q1 2026, down 13.57% year-on-year from -$919834.7 in Q1 2025, and down 100.47% on a QoQ basis from $170.2 million in Q4 2025.
Jade Biosciences (JBIO) has 6 years of Cash from Financing Activities data on file, last reported at -$795000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 13.57% year-over-year to -$795000.0; the trailing twelve-month figure through Mar 2026 stood at $360.7 million (up 93.84% YoY), and the FY2025 full-year result was $360.8 million, up 1318.84% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$795000.0, down from $170.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $191.3 million in Q2 2025 and bottomed at -$795000.0 in Q1 2026.
- The 5-year median for Cash from Financing Activities is $463000.0 (2023), against an average of $45.7 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities surged 473760.0%; it then slumped 248.62% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $357000.0 in 2022, then increased by 29.69% to $463000.0 in 2023, then jumped by 19770.41% to $92.0 million in 2024, then surged by 84.96% to $170.2 million in 2025, then tumbled by 100.47% to -$795000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$795000.0 (Q1 2026), $170.2 million (Q4 2025), and $191.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | -795,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -795,000.00 |
| Mar 31, 2026 | -795,000.00 |
| Dec 31, 2025 | 170.16 Mn |
| Dec 31, 2025 | 170.16 Mn |
| Jun 30, 2025 | 191.31 Mn |
| Jun 30, 2025 | 191.31 Mn |
| Mar 31, 2025 | -700,000.00 |
| Mar 31, 2025 | -700,000.00 |
| Dec 31, 2024 | 92.00 Mn |
| Dec 31, 2024 | 92.00 Mn |
| Sep 30, 2024 | 94.77 Mn |
| Sep 30, 2024 | 94.77 Mn |
| Mar 31, 2024 | 471,000.00 |
| Mar 31, 2024 | 471,000.00 |
| Dec 31, 2023 | 463,000.00 |
| Dec 31, 2023 | 463,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 45.29 Mn |
| Jun 30, 2023 | 45.29 Mn |
| Mar 31, 2023 | 223,000.00 |
| Mar 31, 2023 | 223,000.00 |
| Dec 31, 2022 | 357,000.00 |
| Dec 31, 2022 | 357,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Dec 31, 2021 | -250,000.00 |
| Dec 31, 2021 | -250,000.00 |
| Sep 30, 2021 | 128.31 Mn |
| Sep 30, 2021 | 128.31 Mn |
| Jun 30, 2021 | 54.51 Mn |
| Jun 30, 2021 | 54.51 Mn |
| Mar 31, 2021 | 7.88 Mn |
| Mar 31, 2021 | 7.88 Mn |